Based on ratings from 3 stock analysts, the Apellis Pharmaceuticals Inc stock price is expected to increase by 54.17% in 12 months. This is calculated by using the average 12-month stock price forecast for Apellis Pharmaceuticals Inc. The lowest target is $24 and the highest is $78. Please note analyst price targets are not guaranteed and could be missed completely.
APLS is a stock in Healthcare which has been forecasted to be worth $46.22 as an average. On the higher end, the forecast price is $78 USD by Justin Kim from Oppenheimer and on the lower end APLS is forecasted to be $24 by Luca Issi from RBC Capital.
These are the latest 20 analyst ratings of APLS.
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
---|---|---|---|---|
Colleen Kusy Baird | Outperform | $55 | Maintains | Nov 7, 2024 |
Yigal Nochomovitz Citigroup | Buy | $51 | Maintains | Nov 6, 2024 |
Greg Harrison Scotiabank | Sector Perform | $30 | Maintains | Nov 6, 2024 |
Salveen Richter Goldman Sachs | Buy | $36 | Maintains | Nov 6, 2024 |
Douglas Tsao HC Wainwright & Co. | Buy | $57 | Maintains | Nov 6, 2024 |
Luca Issi RBC Capital | Sector Perform | $24 | Maintains | Nov 6, 2024 |
Biren Amin Piper Sandler | Neutral | $32 | Maintains | Nov 6, 2024 |
Joseph Stringer Needham | Buy | $60 | Maintains | Nov 6, 2024 |
Tazeen Ahmad B of A Securities | Buy | $47 | Maintains | Nov 6, 2024 |
Justin Kim Oppenheimer | Outperform | $40 | Maintains | Nov 6, 2024 |
Derek Archila Wells Fargo | Equal-Weight | $30 | Maintains | Nov 6, 2024 |
Luca Issi RBC Capital | Sector Perform | $25 | Reiterates | Nov 4, 2024 |
Graig Suvannavejh Mizuho | Neutral | $38 | Maintains | Oct 24, 2024 |
Greg Harrison Scotiabank | Sector Perform | $35 | Initiates | Oct 16, 2024 |
Lachlan Brown William Blair | Outperform | Initiates | Oct 16, 2024 | |
Derek Archila Wells Fargo | Equal-Weight | $43 | Maintains | Sep 24, 2024 |
Colleen Kusy Baird | Outperform | $92 | Maintains | Sep 23, 2024 |
Joseph Stringer Needham | Buy | $85 | Reiterates | Sep 20, 2024 |
Graig Suvannavejh Mizuho | Neutral | $39 | Maintains | Sep 20, 2024 |
Anupam Rama JP Morgan | Overweight | $57 | Maintains | Sep 13, 2024 |
When did it IPO
2017
Staff Count
702
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Dr. Cedric Francois M.D., Ph.D.
Market Cap
$3.73B
In 2023, APLS generated $396.6M in revenue, which was a increase of 425.83% from the previous year. This can be seen as a signal that APLS's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Summary - Sales of the company's leading commercial product fell short of expectations.
Why It Matters - Underperformance in sales can signal weak demand or competitive pressures, potentially leading to lower revenue projections and impacting stock valuation negatively.
Summary - Apellis Pharmaceuticals' stock fell after third-quarter sales for its eye drug, Syfovre, significantly missed Wall Street expectations.
Why It Matters - Apellis stock drop signals potential revenue issues and concerns about product demand, impacting investor confidence and future growth projections.
Summary - Apellis Pharmaceuticals will hold its Q3 2024 earnings conference call on November 5, 2024, at 8:30 AM ET, featuring key executives and various financial analysts.
Why It Matters - The Q3 earnings call for Apellis Pharmaceuticals is a key event for assessing financial performance, strategic direction, and market outlook, influencing stock valuations and investment decisions.
Summary - Apellis Pharmaceuticals (Nasdaq: APLS) reported its Q3 2024 financial results and business highlights on November 5, 2024.
Why It Matters - Apellis Pharmaceuticals' Q3 2024 financial results can indicate its growth, profitability, and market position, influencing stock performance and investor sentiment.
Summary - Apellis Pharmaceuticals (APLS) reported a quarterly loss of $0.46 per share, missing the estimate of $0.32. This is an improvement from a loss of $1.17 per share a year earlier.
Why It Matters - Apellis's larger-than-expected quarterly loss may signal ongoing financial challenges, potentially affecting stock performance and investor sentiment amid recovery from last year's higher losses.
Summary - Apellis Pharmaceuticals (APLS) reported revenue and EPS for Q3 2024. Investors should compare these figures with Wall Street estimates and year-ago performance.
Why It Matters - Comparing Apellis Pharmaceuticals' revenue and EPS to Wall Street estimates and previous year data provides insight into growth potential and market expectations, influencing stock valuation.